Arrakis TherapeuticsArrakis Therapeutics
AT

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Mas

2014Active52
About
Arrakis Therapeutics is pioneering a new class of genetic medicines called RNA-targeted small molecules (rSMs) to unlock new biology and create oral medicines. Their robust technology platform and toolkit enable the industrialization of rSM discovery, with a growing pipeline of programs aimed at treating patients. Arrakis is currently advancing an rSM drug candidate to address the root cause of Myotonic Dystrophy Type 1 (DM1).

Technology stack

detected 2026-06-04
Est. monthly stack spend~$450/mo
CDN
Cloudflare
Emailunknown
Stack
jQueryWordPress
Analytics
Google Analytics 4
SEO
Yoast SEO
Performance

Company Timeline

Reddit
What people say on Reddit
(4)

Reddit sentiment regarding Arrakis Therapeutics is mixed, with some posts highlighting positive business developments and others reporting layoffs.

2 positive0 mixed2 negative
Reddit
r/biotechu/Veritaz27Apr 28, 2026Negative

Arrakis Therapeutics Layoff <MA>. Word on the street is Arrakis Therapeutics just recently announced layoff in order to consolidate resources around their lead asset.

View on Reddit
Reddit
r/biotechu/H2AK119ubMar 3, 2024Negative

Arrakis Therapeutics reduces headcount by 20%.

View on Reddit
Reddit
r/buzzfeedbotu/autobuzzfeedbotSep 7, 2021Positive💎

6 top Boston biotech upstarts that VCs say are poised to take off. Arrakis Therapeutics Dyno Therapeutics Flare Therapeutics Generate Biomedicines Korro Bio Neutrolis Link to article

View on Reddit
Reddit
r/chpresseschauu/transpostmetaApr 8, 2020Positive

Pharmaunternehmen - Roche schliesst Lizenzvereinbarung mit Arrakis Therapeutics — Der Pharmakonzern Roche hat sich auf eine Lizenzvereinbarung mit dem US-Biotechunternehmen Arrakis Therapeutics geeinigt..

View on Reddit

Pulled from public Reddit discussions. Quotes are excerpts; click through to read the full thread.

Frequently asked

What does Arrakis Therapeutics do?

Arrakis Therapeutics is pioneering a new class of genetic medicines called RNA-targeted small molecules (rSMs) to unlock new biology and create oral medicines. Their robust technology platform and toolkit enable the industrialization of rSM discovery, with a growing pipeline of programs aimed at treating patients. Arrakis is currently advancing an rSM drug candidate to address the root cause of Myotonic Dystrophy Type 1 (DM1).

How much funding has Arrakis Therapeutics raised?

Arrakis Therapeutics has raised a total of $175M in funding. The most recent round on record is Series B.

Where is Arrakis Therapeutics headquartered?

Arrakis Therapeutics is headquartered in Waltham, United States.

When was Arrakis Therapeutics founded?

Arrakis Therapeutics was founded in 2014.

What industry does Arrakis Therapeutics operate in?

Arrakis Therapeutics operates in Biotech, Drug Discovery, RNA Therapeutics, Small Molecule Drugs, HealthTech.

How many employees does Arrakis Therapeutics have?

Arrakis Therapeutics has approximately 52 people on record.